 A 42-year-old woman with a germline BRCA2 mutation and recurrent low-grade endometrioid endometrial adenocarcinoma experienced clinical and radiographic response to the poly ( ADP ribose) polymerase ( PARP) inhibitor , olaparib. Molecular and treatment factors are discussed.